Showing results (311-320 of 409) with videos related to

Sort By:
Pageof 41
Critical Care (London, England)|November 10, 2005
Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control studyAnne-Cornélie J M de Pont, Kamran Bakhtiari, Barbara A Hutten, et al.
Thrombosis Journal|October 18, 2007
Influenza infection and risk of acute pulmonary embolismMatthijs van Wissen, Tymen T Keller, Brechje Ronkes, et al.
Clinical Therapeutics|January 27, 2009
Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedemaRakesh S Birjmohun, G Kees Hovingh, Erik S G Stroes, et al.
Blood|April 19, 2003
Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumoniaAnita W Rijneveld, Sandrine Florquin, Paul Bresser, et al.
The Journal of Infectious Diseases|June 8, 2004
Inhibition of the tissue factor/factor VIIa pathway does not influence the inflammatory or antibacterial response to abdominal sepsis induced by Escherichia coli in miceSebastian Weijer, Saskia H H F Schoenmakers, Sandrine Florquin, et al.
Journal of the Neurological Sciences|December 16, 2014
Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic strokeDominick J H McCabe, Stephen J X Murphy, Richard Starke, et al.
The Journal of Infectious Diseases|October 8, 2010
Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumoniaMarcel Schouten, Cornelis van 't Veer, Florry E van den Boogaard, et al.
Journal of Hypertension|March 5, 2011
Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisisBert-Jan H van den Born, Ester C Löwenberg, Niels V van der Hoeven, et al.
Seminars in Thrombosis and Hemostasis|September 30, 2009
Improving antithrombotic management in patients with atrial fibrillation: current status and perspectivesMarcel Levi, F D Richard Hobbs, Alan K Jacobson, et al.
Kidney International|April 18, 2020
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatmentEric Rondeau, Marie Scully, Gema Ariceta, et al.
Pageof 41